Journal article

Mitoxantrone, More than Just Another Topoisomerase II Poison

Benny J Evison, Brad E Sleebs, Keith G Watson, Don R Phillips, Suzanne M Cutts



Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is commonly applied in the treatment of breast and prostate cancers, lymphomas, and leukemias. A comprehensive overview of the drug's molecular, biochemical, and cellular pharmacology is presented here, beginning with the cardiotoxic nature of its predecessor doxorubicin and how these properties shaped the pharmacology of mitoxantrone itself. Although mitoxantrone is firmly established as a DNA topoisomerase II poison within mammalian cells, it is now clear that the drug interacts with a much broader range of biological macromolecules both covalently and noncovalently..

View full abstract

University of Melbourne Researchers


Awarded by CASS Foundation

Awarded by National Health and Medical Research Council

Awarded by Australian Research Council

Funding Acknowledgements

This work was supported in part by grants received from the CASS Foundation (SM-07-1547 and SM-08-1971), the National Health and Medical Research Council (APP 487333), and a Future Fellowship from the Australian Research Council (FT0991923).